+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neurotransmitter"

From
From
From
Myotonic Dystrophy - Pipeline Insight, 2024 - Product Thumbnail Image

Myotonic Dystrophy - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 80 Pages
  • Global
From
Epilepsy - Pipeline Insight, 2024 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Migraine - Pipeline Insight, 2024 - Product Thumbnail Image

Migraine - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Parkinson's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Parkinson's disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 230 Pages
  • Global
From
Lewy Body Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Lewy Body Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Essential tremor - Pipeline Insight, 2024 - Product Thumbnail Image

Essential tremor - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 80 Pages
  • Global
From
Brain Hemorrhage - Pipeline Insight, 2024 - Product Thumbnail Image

Brain Hemorrhage - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 75 Pages
  • Global
From
Dravet Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Dravet Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Subarachnoid Hemorrhage - Pipeline Insight, 2024 - Product Thumbnail Image

Subarachnoid Hemorrhage - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Spinocerebellar Ataxias - Pipeline Insight, 2024 - Product Thumbnail Image

Spinocerebellar Ataxias - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 100 Pages
  • Global
From
Tourette Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Tourette Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Gilles de la Tourette's syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Gilles de la Tourette's syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 40 Pages
  • Global
From
Dementia with Diabetes - Pipeline Insight, 2024 - Product Thumbnail Image

Dementia with Diabetes - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Spasmodic-torticollis - Pipeline Insight, 2024 - Product Thumbnail Image

Spasmodic-torticollis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Refractory status epilepticus - Pipeline Insight, 2024 - Product Thumbnail Image

Refractory status epilepticus - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
Vascular Dementia - Pipeline Insight, 2024 - Product Thumbnail Image

Vascular Dementia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Loading Indicator

The Neurotransmitter market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neurotransmitters are chemicals that are released by neurons to send signals to other cells. These drugs are used to treat a variety of neurological disorders, including depression, anxiety, and schizophrenia. Neurotransmitter drugs work by either increasing or decreasing the amount of neurotransmitters in the brain. The Neurotransmitter market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and Merck. Other companies such as Novartis, AstraZeneca, and Johnson & Johnson also have a presence in the Neurotransmitter market. Show Less Read more